An update on new anticoagulant drugs

Öz

Abstract. The conventional management of thrombotic and cardiovascular disorders is based on the use of heparin, oral anticoagulants and aspirin. Despite remarkable progress in life sciences, these drugs still remain a challenge and mystery to us, and their use is far from optimized. The development of low molecular weight heparins and the synthesis of heparinomimetics, such as the chemically synthesized pentasaccharide, represent a refined use of heparin. Additional drugs from this knowledge will continue to develop; however, none of these drugs will match the polypharmacology of heparin. Aspirin still remains the leading drug in the management of thrombotic and cardiovascular disorders. The newer antiplatelet drugs such as ADP receptor inhibitors, GPIIb/IIIa inhibitors and other specific inhibitors have limited effects and have been tested in patients who have already been treated with aspirin. Warfarin provides a convenient and affordable approach in the long-term outpatient management of thrombotic disorders. The optimized use of these drugs still remains to be the approach of choice to manage thrombotic disorders. The new anticoagulant targets, including specific sites in the hemostatic network such as tissue factor, individual clotting factors (IIa, VIIa, IXa, Xa, XIIa and XIIIa), recombinant forms of serpins (antithrombin, heparin co-factor II and tissue factor pathway inhibitors), recombinant activated protein C, thrombomodulin and site specific serine proteases inhibitors complexes have also been developed. There is a major thrust on the development of orally bioavailable anticoagulant drugs (anti-Xa and IIa agents), which are slated to replace oral anticoagulants. Both the anti-factor Xa ( Rivaroxaban and Apixaban) antithrombin (Dabigatran) agents have been developed for oral use and have provided impressive clinical outcomes in sponsor trials for the post surgical prophylaxis of venous thrombosis; however, safety concerns related to liver enzyme elevations and thrombosis rebound have been reported with their use. For these reasons the US FDA did not approve the orally active antithrombin agent Ximelagatran for several indications.  More recently the Columbian health authorities reject dabigatran for similar reasons.   The synthetic pentasaccharide (Fondaparinux) has undergone an aggressive clinical development. Unexpectedly, Fondaparinux also produced major bleeding problems at minimal dosages. Fondaparinux represents only one of the multiple pharmacologic effects of heparins. Thus, its therapeutic index will be proportionately narrower.  The methylated pentasaccharide, namely Idraparinux, is effective for long term prophylaxis, but its use is associated with bleeding.  Other forms of pentasaccharide such as the biotinylated form which can be reversed with fucoidin are also developed.   The newer antiplatelet drugs have added a new dimension in the management of thrombotic disorders. The favorable clinical outcomes with aspirin and Clopidogrel have validated COX-1 and P2Y₁₂ receptors as targets for new drug development. Prasugrel, a novel thienopyridine, Cangrelor and AZD 6140 represent newer P2Y₁₂ antagonists. Cangrelor and AZD 6140 are direct inhibitors, whereas Prasugrel requires metabolic activation. While clinically effective, recent results have prompted a closure of a large clinical trial with Prasugrel due to bleeding.  The newer anticoagulant and antiplatelet drugs are attractive for several reasons; however, none of these are expected to replace the conventional drugs in poly-therapeutic approaches. Heparins, warfarin and aspirin will continue to play a major role in the management of thrombotic and cardiovascular disorders beyond 2010.

 

Key word: New anticoagulant drugi

Anahtar Kelimeler

• -

Kaynakça

1. 1. Fareed J, Lewis B, Callas D, et al. Antithrombin agents: The new class of anticoagulant and antithrombin drug. Clin Appl Throm Hemost 1999; 5: S45-55. 2. Fareed J, Haas S, Sasahara A. Differentiation of low molecular weight heparins: Applied and clinical considerations. Sem Thromb Hemost 1999; 25: 1-47.
2. 3. Fareed J, Messmore HL. Clopidogrel, a new ADP receptor antagonist: clinical development. Sem Thromb Hemost 1999; 25: 1-84.
3. 4. Fareed J, Walenga JM, Hoppensteadt D, Kaiser B, Jeske W. Factor Xa inhibitors in the control of thrombogenesis. Haemost 1999; 19: 55-62.
4. 5. Bick RL, Fareed J. Low molecular weight heparins: differences and similarities in approved preparations in the United States. Clin Appl Thromb Hemost 1999; 5: 63-66.
5. 6. Fareed J and Hoppensteadt D. The management of thrombotic and cardiovascular disorders in the 21st century. In: Sasahar and Laoscalzo, eds. New Therapeutic Agents in Thrombosis and Thrombolysis. New York: Marcel Dekkerl 2005: 687-693.
6. 7. Albers GW, Amarenco P, Easton JD, et al. Antithrombotic and thrombolytic therapy for ischemic stroke. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 483-512.
7. 8. Harrington RA, Becker RC, Ezekowitz M, et al.. Antithrombotic therapy for coronary artery disease. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 513S- 548S. 9. Stein PD, Schunemann HJ, Dalen JE, et al. Antithrombotic therapy during percutaneous coronary intervention: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126: 576S-599S.
8. 10. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 338S-400S.

9. 11. Chapman TM, Goa KL. Bemiparin: a review of it’s use in the prevention of venous thromboembolism and treatment of deep vein thrombosis. Drugs 2003; 63: 2357-2377.
10. 12. Laux V, Just M, Rosenburg R et al. and Viskov C. The new anticoagulant octaparin displays high antithrombotic action in venous thrombosis in rabbits and rats without impairment of hemostasis. J Thromb Hemost. 2005; 3: P0601.
11. 13. DiNisio M, Middeldorp S, Buller H. Direct thrombin inhibitors. N Engl J Med 2005; 353: 1028-1040.
12. 14. Lubenow N, Eichler P, Lietz T, et al. Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies. Blood 2004; 104: 3072-3077.
13. 15. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103: 1838-1843.
14. 16. Lewis BE, Wallis DE, Leya F, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003; 163: 1849-1856.
15. 17. Eriksson BI, Wille-Jorgensen P, Kalebo P, et al. A comparison of recombinant hirudin with lowmolecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997; 337: 1329-1335.
16. 18. Eriksson BI, Ekman S, Lindbratt S, et al. Prevention of thromboembolism with use of recombinant hirudin: results of a double blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. J Bone Joint Surg Am 1997; 79: 326-333.
17. 19. Carswell C, Plasker G. Bivalirudin: a review of its potential place in the management of acute coronary syndromes. Drugs 2002; 62: 841-870.
18. 20. Aherns I, Smith B, Bode C, Peter K. Direct thrombin inhibition with bivalirudin as an antithrombotic strategy in general and interventional cardiology. Expert Opin Drug Metab Toxicol 2007; 3: 609-620.
19. 21. Carswell C, Plosker G. Bivalirudin: a review of its potential place in the management of acute coronary syndromes. Drugs 2002; 62: 841-870.
20. 22. Dyke C, Aldea G, Koster A, et al. Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor 4 / heparin antibodies. Ann Thorac Surg 2007; 84: 836-839.
21. 23. Pappalardo F, Franco A, Crescenzi G, et al. Successful use of bivalirudin for cardiopulmonary bypass in a patient with heparin allergy. Perfusion 2007; 22: 67-69.
22. 24. Leone G, Rossi E, Leone AM, DeStefano V. Novel Antithrombotic Agents: Indirect Synthetic Inhibitors of Factor Xa and Direct Thrombin Inhibitors. Evidences from Clinical Studies. Curr. Med. Chem. – Cardiovascular Hematological Agents 2004; (2): 311-326.
23. 25. Bauer K. New Anticoagulants. Hematology 2006 450-456. 26. LaMonte MP, Nash ML, Wang DZ, et al. Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study. Stroke 2004; 35: 1677-1682.
24. 27. Eriksson BI, Dahl OE, Buller H, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement, The BISTRO II randomized trial. J Thromb Haemost 2005; 3: 103-111.
25. 28. Samama MM, Walenga J, Kaiser B, et al. Specific factor Xa inhibitors. In Cardiovascular Thrombosis: Thrombocardiology. Eds Verstraete M, Fuster V, Topol E. Lippincott-Raven, Brussels, Belgium, 1997; 173-188.
26. 29. Weitz J, Hirsh J. New antithronbotic agents. Chest 2001; 119: 95-107. 30. Walenga JM, Jeske WP, Samama MM, et al. Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent. Expert Opin Investig Drugs 2002; 11: 397-407.
27. 31. Lassen MR, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus preoperative enoxaparin for the prevention of venous thromboembolism in elective hip-replacement surgery: a randomized double-blind comparison. Lancet 2002; 359: 1715-1720.
28. 32. Turpie AGG, Bauer KA, Erikkson BI, et al. Postoperative fondaparinux versus preoperative enoxaparin for the prevention of venous thromboembolism in elective hip-replacement surgery: a randomized double-blind comparison. Lancet 2002; 359: 1721-1726.
29. 33. Bauer KA, Eriksson BI, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001; 345: 1305-1310.
30. 34. Ericksson BI, Bauer KA, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hipfracture surgery. N Engl J Med 2001; 345: 1298- 1304.
31. 35. Buller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004; 140: 867-873.
32. 36. Buller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349: 1695-1702.
33. 37. Simons ML, Bobbink IW, Boland J, et al. A dosefinding study of fondaparinux in patients with nonST-segment elevation in acute coronary syndromes. The Pentasaccharide in Unstable Angina (PENTUA) Study. J Am Coll Cardiol 2004; 43: 2183-2190.
34. 38. Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux with enoxaparin in acute coronary syndromes. N Engl J Med. 2006; 354: 1464-1476.
35. 39. Herbert JM, Heravlet JP, Bernat A, et al. Biochemical and pharmacologic properties of SanOrg 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998; 91: 4197-4205.
36. 40. PERSIST investigators. A novel, long-acting synthetic factor Xa inhibitor (SanOrg 34006) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. J Thromb Haemost 2004; 21: 47-53.
37. 41. Idrabioparinux,a biotinylated long-acting anticoagulant in the treatment of deep vein thrombosis (EQUINOX study): safety, efficacy and reversibility by avidin. Blood 2008; 12 (11): abstract 32.
38. 42. Turpie AG, Fisher WD, Bauer KA, et al. BAY 59- 7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II doseranging study. J Thromb Haemost 2005; 311: 2479- 2486.
39. 43. Erikkson BI, Borris L, Dahl O, et al. Oral, direct factor Xa inhibition with Bay 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006; 41: 121- 128.
40. 44. Lee WM, Larrey D, Olsson R et al. Hepatic findings in long term clinical trials of ximelagatran. Drug Safety 2005; 28: 351-370.
41. 45. Lassen M, Gallus AS, Pineo GF, et al. Randomized double blind comparison of apixaban with enoxaparin for thromboprophylaxis after knee replacement. The advance trial. Blood 2008; 12 (11): abstract 31.
42. 46. Weitz JI, Conolly J, Kunitada S et al. Randomized parallel group, multicenter study evaluating safety of DU 176b compared with warfarin in subjects with new valvular atrial fibrillation. Blood 2008; 12(11): abstract 33.
43. 47. Weitz J, Stuart J, Connolly J, et al. Randomized double blind, multidose efficacy and biomarker study of the oral factor Xa inhibitor Du 176b compared with placebo for prevention of venous thromboembolism in patients with total knee replacement Blood 2008; 12(11): abstract 34.
44. 48. Turpie AGG, Bauer K, Davidson B, et al. Once daily oral rivaroxiban compared with subcutaneous enoxaparin every 12 hours for thromboprophylaxis after total knee replacement. Blood 2008; 12(11): abstract 35.
45. 49. Turpie AGG, Lassen M, Kakkar AJ, et al. A pooled analysis of four pivotal studies of rivaroxiban for the prevention of venous thromboembolism after orthopedic surgery. Blood 2008; 12(11): abstract 36.
46. 50. Gibson M, Mega J, Hamett C, et al. ATLAS ACS TIMI 4b study, Late Breaking AHA Scientific Sessions 2008, Altanta , Georgia, Nov 8, 2008.